• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA Updates Guidance for NonCOVID-19 Clinical Trials

MHRA Updates Guidance for NonCOVID-19 Clinical Trials

February 22, 2021

Sponsors of nonCOVID-19 trials should assess how trial participants receiving COVID-19 vaccinations could impact their studies, according to updated guidance from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

The agency also said protocols for new nonCOVID-19 trials should address whether or how to provide vaccinations to participants in order to avoid substantial protocol amendments in the future.

If a sponsor of an ongoing trial determines the vaccine would have no interaction with the drug being tested, they can inform the agency as part of their trials’ next substantial amendment, labeling it a “nonsubstantial update.”

But in cases where potential issues are identified — such as in trials testing immune-related mechanisms — a substantial amendment to the MHRA and the appropriate research ethics committee approval is required. In such cases, trial protocols must consider if a minimal period of time must separate dosing with the investigational product and administration of the vaccine. MHRA also requires a risk-benefit discussion to support sponsors’ decisions.

In blinded trials, MHRA said sponsors should consider whether their trial subjects would require unblinding in order to receive a COVID-19 vaccine. Although sponsors can unblind subjects on an individual basis, the agency said sponsors should encourage them to remain in the trial. “They should ideally not be withdrawn, unless they explicitly request this,” MHRA said.

Read the updated guidance here: http://bit.ly/3qEVDvp. MHRA said it is working on separate guidance for COVID-19 vaccine trials.

COVID-19
  • Related Directories

    Veklury (remdesivir)

    Pfizer-BioNtech COVID-19 Vaccine

    Moderna COVID-19 Vaccine (mRNA-1273)

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing